Pharmaceutical Preparations · MELBOURNE, VIC 3000, Australia
$5.07
-1.46% (-$0.07)2026-06-24
Smart-Money SignalNeutral · 51/100— Insider open-market flow is flat over 90 days
Price Performance
Historical data including institutional events
Company Profile
D
David Stamler
CEO & Executive Director
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinsonâs disease. The companyâs lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinsonâs disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as biomarkers of progression in multiple system atrophy. The company also operates drug discovery platform that generates patentable chemical compounds to treat the underlying pathology of neurological diseases. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia.
- Founded
- 1997
- Employees
- 9
- Headquarters
- MELBOURNE, VIC 3000, Australia
- Website
- alteritytherapeutics.com
Peer ComparisonRevenue ($B)
▾Loading company sections...